Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 24;80(2):461-468.
doi: 10.1093/cid/ciae427.

Timing of Influenza Antiviral Therapy and Risk of Death in Adults Hospitalized With Influenza-Associated Pneumonia, Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012-2019

Mark W Tenforde  1 , Kameela P Noah  1 , Alissa C O'Halloran  1 , Pam Daily Kirley  2 , Cora Hoover  3 , Nisha B Alden  4 , Isaac Armistead  4 , James Meek  5 , Kimberly Yousey-Hindes  5 , Kyle P Openo  6   7   8 , Lucy S Witt  6   7 , Maya L Monroe  9 , Patricia A Ryan  9 , Anna Falkowski  10 , Libby Reeg  10 , Ruth Lynfield  11 , Melissa McMahon  11 , Emily B Hancock  12 , Marisa R Hoffman  12 , Suzanne McGuire  13 , Nancy L Spina  13 , Christina B Felsen  14 , Maria A Gaitan  14 , Krista Lung  15 , Eli Shiltz  15 , Ann Thomas  16 , William Schaffner  17 , H Keipp Talbot  17 , Melanie T Crossland  18 , Andrea Price  18 , Svetlana Masalovich  1 , Katherine Adams  1 , Rachel Holstein  1 , Devi Sundaresan  1 , Timothy M Uyeki  1 , Carrie Reed  1 , Catherine H Bozio  1 , Shikha Garg  1
Affiliations

Timing of Influenza Antiviral Therapy and Risk of Death in Adults Hospitalized With Influenza-Associated Pneumonia, Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012-2019

Mark W Tenforde et al. Clin Infect Dis. .

Abstract

Background: Pneumonia is common in adults hospitalized with laboratory-confirmed influenza, but the association between timeliness of influenza antiviral treatment and severe clinical outcomes in patients with influenza-associated pneumonia is not well characterized.

Methods: We included adults aged ≥18 years hospitalized with laboratory-confirmed influenza and a discharge diagnosis of pneumonia over 7 influenza seasons (2012-2019) sampled from a multistate population-based surveillance network. We evaluated 3 treatment groups based on timing of influenza antiviral initiation relative to admission date (day 0, day 1, days 2-5). Baseline characteristics and clinical outcomes were compared across groups using unweighted counts and weighted percentages accounting for the complex survey design. Logistic regression models were generated to evaluate the association between delayed treatment and 30-day all-cause mortality.

Results: A total of 26 233 adults were sampled in the analysis. Median age was 71 years and most (92.2%) had ≥1 non-immunocompromising condition. Overall, 60.9% started antiviral treatment on day 0, 29.5% on day 1, and 9.7% on days 2-5 (median, 2 days). Baseline characteristics were similar across groups. Thirty-day mortality occurred in 7.5%, 8.5%, and 10.2% of patients who started treatment on day 0, day 1, and days 2-5, respectively. Compared to those treated on day 0, adjusted odds ratio for death was 1.14 (95% confidence interval [CI], 1.01-1.27) in those starting treatment on day 1 and 1.40 (95% CI, 1.17-1.66) in those starting on days 2-5.

Conclusions: Delayed initiation of antiviral treatment in patients hospitalized with influenza-associated pneumonia was associated with higher risk of death, highlighting the importance of timely initiation of antiviral treatment at admission.

Keywords: antiviral; hospitalization; influenza; mortality; oseltamivir.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. K. Y.-H., J. M., I. A., and W. S. report grants from the CDC, during the conduct of the study. A. F. and L. R. report grants from the Michigan Department of Health and Human Services, during the conduct of the study. M. L. M. reports grants from the CDC Emerging Infections Program, during the conduct of the study. R. L. reports grants from the CDC Emerging Infections Program cooperative agreement, during the conduct of the study, and fee for work as Associate Editor for the American Academy of Pediatrics Report of the Committee on Infectious Diseases (Red Book), which donated to the Minnesota Department of Health. H. K. T. reports funding from CDC for this work and other areas of research. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Association between timing of influenza antiviral therapy and 30-day mortality. Abbreviations: CI, confidence interval; OR, odds ratio.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden averted by vaccination. 2024. Available at: https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html. Accessed 16 October 2023.
    1. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018; 391:1285–300. - PMC - PubMed
    1. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68:e1–47. - PMC - PubMed
    1. Appiah GD, Chaves SS, Kirley PD, et al. Increased antiviral treatment among hospitalized children and adults with laboratory-confirmed influenza, 2010–2015. Clin Infect Dis 2017; 64:364–7. - PMC - PubMed
    1. Tenforde MW, Cummings CN, O’Halloran AC, et al. Influenza antiviral use in patients hospitalized with laboratory-confirmed influenza in the United States, FluSurv-NET, 2015–2019. Open Forum Infect Dis 2023; 10:ofac681. - PMC - PubMed

Publication types

Substances